Kathmere Capital Management LLC purchased a new position in Humana Inc. (NYSE:HUM – Free Report) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 456 shares of the insurance provider’s stock, valued at approximately $170,000.
Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Rakuten Securities Inc. acquired a new stake in shares of Humana in the 4th quarter valued at about $25,000. Cetera Trust Company N.A acquired a new stake in Humana in the fourth quarter valued at approximately $28,000. Private Wealth Management Group LLC bought a new stake in shares of Humana during the fourth quarter valued at approximately $32,000. Carolinas Wealth Consulting LLC raised its position in shares of Humana by 274.1% during the fourth quarter. Carolinas Wealth Consulting LLC now owns 101 shares of the insurance provider’s stock worth $46,000 after purchasing an additional 74 shares during the period. Finally, Turtle Creek Wealth Advisors LLC bought a new position in shares of Humana in the 4th quarter worth $55,000. 92.38% of the stock is owned by institutional investors.
Humana Stock Performance
Shares of HUM stock traded up $4.64 on Friday, hitting $363.62. 1,076,306 shares of the stock were exchanged, compared to its average volume of 1,396,067. The firm’s 50 day moving average is $367.90 and its two-hundred day moving average is $347.35. Humana Inc. has a one year low of $298.61 and a one year high of $530.54. The firm has a market capitalization of $43.78 billion, a PE ratio of 22.64, a P/E/G ratio of 2.09 and a beta of 0.51. The company has a current ratio of 1.66, a quick ratio of 1.67 and a debt-to-equity ratio of 0.70.
Wall Street Analysts Forecast Growth
HUM has been the topic of several research reports. Deutsche Bank Aktiengesellschaft upped their price objective on shares of Humana from $341.00 to $349.00 and gave the stock a “hold” rating in a report on Friday. UBS Group dropped their price target on shares of Humana from $334.00 to $326.00 and set a “neutral” rating on the stock in a research report on Thursday, April 25th. Truist Financial boosted their price objective on Humana from $355.00 to $400.00 and gave the stock a “hold” rating in a report on Monday, July 15th. Oppenheimer raised their target price on Humana from $370.00 to $400.00 and gave the company an “outperform” rating in a report on Thursday. Finally, Robert W. Baird began coverage on Humana in a research report on Thursday, May 30th. They issued a “neutral” rating and a $374.00 price target for the company. Fourteen investment analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to MarketBeat, Humana currently has a consensus rating of “Hold” and an average price target of $403.55.
About Humana
Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
Recommended Stories
- Five stocks we like better than Humana
- Market Cap Calculator: How to Calculate Market Cap
- Market Crash? No Problem for DoorDash Stock’s Impressive Earnings
- What is Put Option Volume?
- Snap’s Stock Plummets on Q2 Revenue Guidance Shortfall
- Overbought Stocks Explained: Should You Trade Them?
- Hims & Hers Stock Falls on DexCom Fears: Analysts Predict Rally
Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc. (NYSE:HUM – Free Report).
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.